Prospective evaluation of the quality of life and safety in patients receiving hepatic artery infusion pump chemotherapy
Surgical Oncology Insight · 2025-09 · 2 (3) · 100159
DOI: 10.1016/j.soi.2025.100159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Oncology Insight, 2025-09. Verfasst von LaDonna E. Kearse und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mayo Clinic.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and Objectives Hepatic Artery Infusion (HAI) Pump placement and subsequent 6+ months of HAI chemotherapy is an intensive treatment regimen available to select patients with colorectal liver metastasis. The effects on quality of life (QOL) from HAI placement and chemotherapy are largely unknown. We aimed to evaluate the use of patient-reported outcome (PRO) surveys to measure the QOL in these patients.
Methods
Patients scheduled for HAI pump placement between 2022 and 2023 were prospectively enrolled. PROs were collected using PROMIS and LASA scales preoperatively, postoperative (POD) days 2, 7, 14, and monthly until 6 months. Complications were recorded using Clavien-Dindo score.
Results
Twelve patients were included. Median [IQR] age at surgery was 55.0 (43.8-62.5) years. All patients successfully initiated HAI and systemic therapy. Mean (± SD) LASA QOL was 8.0 ± 1.9 preoperatively, 6.4 ± 1.8 on POD 2, 7.2 ± 1.3 at 1 month, 8.2 ±1.3 at 3 months, and 7.5 ± 1.7 at 6 months. LASA QOL, pain severity, and fatigue scores returned to baseline in 8/11, 10/11, and 8/11 patients at 3 months, respectively. At 6 months, 3/11, 9/11, and 7/11 patients reported return to baseline social, pain, and fatigue scores.
Conclusions
PROMIS and LASA measures are potential tools for evaluating PROs in patient undergoing HAI therapy. Preliminary data suggests baseline QOL mostly returns within 3 months of HAI placement, and initiation of HAI treatment does not appear to significantly impact QOL. These results support the inclusion of such PROs in future randomized trials to assess effects of HAI chemotherapy on QOL.
Förderung
- Mayo Clinic
Zitieren
APA
Kearse, L. E., Day, C., Zironda, A., Mitchell, J., Jin, Z., Warner, S. G., & Thiels, C. A. (2025). Prospective evaluation of the quality of life and safety in patients receiving hepatic artery infusion pump chemotherapy. Surgical Oncology Insight, 2(3), 100159. https://doi.org/10.1016/j.soi.2025.100159
Vancouver
Kearse LE, Day C, Zironda A, Mitchell J, Jin Z, Warner SG, et al. Prospective evaluation of the quality of life and safety in patients receiving hepatic artery infusion pump chemotherapy. Surgical Oncology Insight. 2025;2(3):100159. doi:10.1016/j.soi.2025.100159
BibTeX
@article{Kearse2025,
author = {Kearse, LaDonna E. and Day, Courtney and Zironda, Andrea and Mitchell, Jessica and Jin, Zhaohui and Warner, Susanne G. and Thiels, Cornelius A.},
title = {Prospective evaluation of the quality of life and safety in patients receiving hepatic artery infusion pump chemotherapy},
journal = {Surgical Oncology Insight},
year = {2025},
volume = {2},
number = {3},
pages = {100159},
doi = {10.1016/j.soi.2025.100159}
}
EUVIMED